Ocular Therapeutix (OCUL) Stock Statistics & Valuation Metrics

Ocular Therapeutix has a market cap or net worth of $2.24B. The enterprise value is $1.58B.

Ocular Therapeutix has 217,691,770 shares outstanding. The number of shares has decreased by -2.65% in one year.

Ocular Therapeutix’s return on equity (ROE) is -0.41 and return on invested capital (ROIC) is -35.53%.

The current PE Ratio of Ocular Therapeutix is ―. Ocular Therapeutix’s PEG ratio is -0.52.

In the last 12 months, Ocular Therapeutix had revenue of 51.82M and earned -265.94M in profits. Earnings per share was -1.42.

In the last 12 months, operating cash flow was -204.88M and capital expenditures -12.01M, giving a free cash flow of -216.89M billion.

Ocular Therapeutix pays an annual dividend of ―, resulting in a dividend yield of ―

Ocular Therapeutix upcoming earnings date is May 11, 2026, After Close (Confirmed).

Ocular Therapeutix as a current ratio of 15.39, with Debt / Equity ratio of 11.76%

In the past 12 months, Ocular Therapeutix has paid 0.00 in taxes.

Ocular Therapeutix EV to EBITDA ratio is -6.47, with an EV/FCF ratio of -7.45.

Ocular Therapeutix has $737.06M in cash and marketable securities with $76.97M in debt, giving a net cash position of $660.09M billion.

Gross margin is 87.35%, with operating margin of -521.04%, and net profit margin of -513.17%.

The average price target for Ocular Therapeutix is $25.38, which is 11.43% higher than the current price. The consensus rating is Strong Buy